Egalet Corp  

(Public, NASDAQ:EGLT)   Watch this stock  
Find more results for EGLT
-0.21 (-3.93%)
After Hours: 5.01 -0.12 (-2.34%)
Jan 18, 6:31PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.06 - 5.65
52 week 4.34 - 10.00
Open 5.24
Vol / Avg. 0.00/1.22M
Mkt cap 116.96M
P/E     -
Div/yield     -
EPS -3.11
Shares 25.19M
Beta     -
Inst. own 100%
Mar 6, 2017
Q4 2016 Egalet Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 15, 2016
Egalet Corp at Stifel Healthcare Conference
Nov 4, 2016
Q3 2016 Egalet Corp Earnings Release
Nov 4, 2016
Q3 2016 Egalet Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -571.79% -253.76%
Operating margin -503.04% -228.72%
EBITD margin - -215.51%
Return on average assets -80.74% -49.73%
Return on average equity -284.29% -86.80%
Employees 78 -
CDP Score - -


600 Lee Rd Ste 100
WAYNE, PA 19087-5624
United States - Map
+1-610-8334200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Officers and directors

Timothy P. Walbert Independent Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Robert Radie President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Stanley J. Musial Chief Financial Officer, Executive Vice President, Secretary
Age: 55
Bio & Compensation  - Reuters
Mark Strobeck Ph.D. Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Paul C. Varki J.D. Senior Vice President, General Counsel
Bio & Compensation  - Reuters
E. Blair Clark-Schoeb Senior Vice President - Communications
Bio & Compensation  - Reuters
Karsten Lindhardt Ph.D. Senior Vice President - Research & Development
Age: 44
Bio & Compensation  - Reuters
Barbara Carlin Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Jeffrey M. Dayno M.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Patrick M. Shea Chief Commercial Officer
Bio & Compensation  - Reuters